Skip to content

Transcranial Alternating Current Stimulation (tACS) in Stuttering

Improving Neural Oscillation and Synchrony Between Motor and Auditory Regions in Stuttering Using Personalized Transcranial Alternating Current Stimulation (tACS)

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06740968
Enrollment
80
Registered
2024-12-18
Start date
2025-08-05
Completion date
2029-12-31
Last updated
2025-09-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stuttering, Adult, Stuttering, Childhood, Stuttering, Developmental

Keywords

tACS, Magnetic resonance imaging, Electroencephalogram, Auditory perturbation, Neural oscillations, Brain stimulation

Brief summary

The purpose of this study is to investigate how mild, noninvasive electrical brain stimulation affects speech relevant brain areas, which may in turn affect speech fluency and speaking-related brain activity in people that stutter. The long-term goal of this study is to test the therapeutic potential of transcranial alternating current stimulation (tACS) for the treatment of stuttering. The study team hypothesizes that if stuttering involves impaired initiation of motor programs, delta-tuned tACS will strengthen communication between brain regions and decrease stuttering. Therefore, delta-tuned sensorimotor tACS will be paired with fluency-induced speech (choral reading), which is hypothesized to decrease stuttering via improved auditory motor integration.

Detailed description

Participants will have screening and baseline visits that include a variety of tests and procedures (i.e. standardized tests of speech, language, hearing test, music training questionnaire, working memory tests, and speech sample to characterize stuttering, magnetic resonance imaging (MRI) and electroencephalography (EEG)). Following these, participants will have 3 sessions (active and sham conditions) and then a one month follow-up phone or video call. Of note, there will be an embedded pilot study to refine the experimental protocol in terms of practicality and feasibility and these participants will not be included in this registration. The only purpose of this embedded study is to refine the protocol and it does not have any health or behavioral outcomes.

Interventions

DEVICEtranscranial alternating current stimulation (tACS)

During each of the 3 stimulation visits, participants will be seated in a comfortable position and a cap will be placed on participant's head similar to a swimming cap. Small electrodes will be placed near the surface of the scalp at certain regions of interest, and a weak electrical current will be passed through the electrodes into speech related brain areas for 20 minutes. The study team will not use current strengths exceeding 2 milliamps (mA).

Sponsors

University of Michigan
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Masking description

Please note that because the most logical interventional study model is a single arm study the study team can't select a masking option. Please note that Participants, Investigators, and Outcomes Assessors will be blinded to active vs. sham stimulation (with the exception of one study investigator that pre-configures the randomization schedule, and this person will not be involved in any assessments/outcomes).

Intervention model description

Participants will all receive the same treatments, however, visits 3 through 5 will have order of conditions (types of stimulation) randomized.

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

for stutterers: * Have normal language, hearing, and cognition * Speak English as the primary language * Currently stutter * Score (per protocol) a certain value on the Stuttering Severity Instrument (SSI-4). * Have not received any treatment for stuttering within the past year

Exclusion criteria

for stutterers: * History of seizures * Major medical or neurological illness (e.g., stroke, serious head trauma, brain infection, Parkinson's disease, etc.) * History of closed head injury with loss of consciousness (e.g., concussion) * Metal or electronic implants such as cochlear implants and pacemakers anywhere in the body * Braids or other hair styling that prevents direct access to the scalp (if removal not possible) * Currently pregnant

Design outcomes

Primary

MeasureTime frameDescription
Change in Phase SynchronizationBaseline (pre-tACS), approximately 3 hours (post-tACS) (visits 3-5)The study will compare EEG data recorded before and after stimulation to determine if tACS contributed to any changes. This will be measured by Phase Locking Value (PLV; measured from 0 to 1) between the two regions targeted by stimulation calculated as \[pre(active-sham)\] - \[post(active-sham)\] at each tACS visit.

Secondary

MeasureTime frameDescription
Percentage of stuttered syllables produced during speech sampleBaseline (before tACS), approximately 3 hours (post-tACS) (visits 3-5)The study will calculate the percentage of stuttered syllables (out of total syllables) in a speech sample. Decreased stuttered syllables represents better outcomes (greater reduction in stuttering).

Other

MeasureTime frameDescription
Percent change in perturbation responseBaseline (before tACS), approximately 3 hours (post-tACS) (visits 3-5)The study will compare the perturbation task from before and after tACS. This is measured by the percent change in perturbation response.
Change in Phase Amplitude CouplingBaseline (before tACS), approximately 3 hours (post-tACS) (visits 3-5)The study will compare EEG data recorded before and after stimulation to determine if tACS contributed to any changes. Phase Amplitude Coupling (PAC) will be calculated within and between the two regions targeted by stimulation calculated as \[pre(active-sham)\] - \[post(active-sham)\] at each tACS visit.

Countries

United States

Contacts

Primary ContactSoo-Eun Chang, PhD
sooeunc@umich.edu734-232-0300
Backup ContactEmily Garnett, PhD
emilyog@med.umich.edu734-232-3371

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026